{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:16:44Z","timestamp":1791101804168,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100012431","name":"Celldex Therapeutics","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100012431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glembatumumab vedotin is an antibody\u2010drug conjugate that produced preliminary clinical activity against advanced melanoma in a phase 1 dose\u2010escalation trial. The objective of the current study was to investigate further the antitumor activity of glembatumumab vedotin at the recommended phase 2 dose in heavily pretreated patients with melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single\u2010arm, phase 2 study enrolled patients with stage IV melanoma who were refractory to checkpoint inhibition and to B\u2010raf proto\u2010oncogene, serine\/threonine kinase (BRAF)\/mitogen\u2010activated protein kinase kinase (MEK) inhibition (in the presence of a BRAF valine mutation at codon 600). Patients received 1.9 mg\/kg glembatumumab vedotin intravenously every 3 weeks until they developed disease progression or intolerance. The primary endpoint was objective response rate (ORR), which was determined according to Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary endpoints included progression\u2010free survival (PFS), duration of response, overall survival (OS), safety, and clinical efficacy versus tumor glycoprotein NMB (gpNMB) expression. Tumor expression of gpNMB was assessed using immunohistochemistry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 62 patients received treatment. The ORR was 11% and the median response duration was 6.0 months (95% confidence interval [CI], 4.1 months to not reached). The median PFS was 4.4 months (95% CI, 2.6\u20105.5 months), and the median OS was 9.0 months (95% CI, 6.1\u201011.7 months). For patients who developed rash during the first cycle versus those who did not, the ORR was 21% versus 7%, respectively, and there was an overall improvement in PFS (hazard ratio, 0.43;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.013) and OS (hazard ratio, 0.43;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.017). The most frequent adverse events were alopecia, neuropathy, rash, fatigue, and neutropenia. With one exception, all evaluable tumors were positive for gpNMB, and 46 of 59 tumors (76%) had 100% gpNMB\u2010positive epithelial cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Glembatumumab vedotin had modest activity and an acceptable safety profile in patients with advanced melanoma who were refractory to checkpoint inhibitors and MEK\/BRAF inhibition. Treatment\u2010related rash may be associated with response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.31892","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T22:56:45Z","timestamp":1548716205000},"page":"1113-1123","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["A phase 2 study of glembatumumab vedotin, an antibody\u2010drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma"],"prefix":"10.1002","volume":"125","author":[{"given":"Patrick A.","family":"Ott","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Pavlick","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology New York University School of Medicine New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Vanderbilt\u2010Ingram Cancer Center Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell L.","family":"Hart","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists and Research Institute Fort Myers, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Infante","sequence":"additional","affiliation":[{"name":"Tennessee Oncology PLLC Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Luke","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology University of Chicago Medical Center Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Lutzky","sequence":"additional","affiliation":[{"name":"Mount Sinai Comprehensive Cancer Center Miami Beach, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal E.","family":"Rothschild","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists West Palm Beach, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Spitler","sequence":"additional","affiliation":[{"name":"St. Mary's Medical Center San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Lance","family":"Cowey","sequence":"additional","affiliation":[{"name":"Northern California Melanoma Center, Baylor University Medical Center  Dallas Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"Northside Hospital Cancer Institute Decatur Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April K.","family":"Salama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Duke University Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[{"name":"Celldex Therapeutics, Inc Hampton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Hawthorne","sequence":"additional","affiliation":[{"name":"Celldex Therapeutics, Inc Hampton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca G.","family":"Bagley","sequence":"additional","affiliation":[{"name":"Celldex Therapeutics, Inc Hampton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Celldex Therapeutics, Inc Hampton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Turner","sequence":"additional","affiliation":[{"name":"Celldex Therapeutics, Inc Hampton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00083-2"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-07-0119"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2797"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2018"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1611"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12107"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25099"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.1896"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1192"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8115"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.5683"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2959"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv324"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200410000-00013"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3181942a1f"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0036"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2008.02.002"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.954460"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1565-4"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac4925"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31892","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31892","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.31892","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:42:29Z","timestamp":1761867749000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1002\/cncr.31892"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31892","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"2018-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}